Engineered immune cells take on Hard-to-Treat prostate cancer
NCT ID NCT06228404
First seen May 03, 2026 · Last updated May 10, 2026 · Updated 1 time
Summary
This early-phase trial tests a new treatment for men with advanced prostate cancer that has stopped responding to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. Up to 18 participants will receive these enhanced cells to see if they are safe and can slow the cancer's growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Changzheng hospital
Shanghai, Shanghai Municipality, 201109, China
Conditions
Explore the condition pages connected to this study.